SGLT inhibitors to treat type 1 diabetes! Astellas Suglat (Igley Net L-Proline) has been approved for new adaptations

Astellas, the Japanese drugmaker, and Kotobuki Pharmaceuticals, a Japanese pharmaceutical company, recently jointly announced that Suglat (ipragliflozin L-proline) had been approved by Japanese regulators for additional adaptations to the treatment of type 1 diabetes, as well as additional dosages and dosages. In the Japanese market, Suglat was approved for type 2 diabetes in January 2014 and went on sale in April 2014.
Suglat is an alternative sodium-glucose co-transport protein 2 (SGLT2) inhibitor found in collaboration with a study by Astellas and Shou Pharmaceuticals. SGLT is a type of membrane protein that exists on the cell surface and transports glucose into the cell. SGLT has two subsypes, SGLT1 and SGLT2, distributed in the small intestine mucous membrane and kidney tubes. SGLT2 plays a key role in near-end renal tube glucose re-absorption. Suglat selectively inhibits SGLT2, which prevents glucose in the renal tube from being successfully re-absorbed into the bloodstream and excreted with the urine, thereby lowering blood sugar levels.
type 1 diabetes is an insulin deficiency disorder that occurs when insulin-producing cells in the pancreas β damaged by the immune system. It is estimated that about 10 million people in Japan may have diabetes, of which type 1 diabetes accounts for about 6%. Suglat will provide a new treatment for people with type 1 diabetes who have insufficient blood sugar control with insulin.
noted that Astellas is not the only player involved in the treatment of type 1 diabetes with SGLT inhibitors. Currently, AstraZeneca's sugar-lowering drug Farxiga (Anda Tang, generic name: dapagliflozin, dagliflozin, dagliflozin) and Sanofi's sugar-lowering drug Zynquista (sotagliflozin, Sogrinide) are also under regulatory review for the treatment of type 1 diabetes, the former being a SGLT2 inhibitor, and the latter a SGLT-1/SGLT-2 dual-effect inhibitor. (Bio Valley)